ANAB Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -82.06%. AnaptysBio, Inc.'s return on equity of -367.62% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

AnaptysBio, Inc. has a consensus price target of $63.91, signalling upside risk potential of 47.6%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that AnaptysBio, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe AnaptysBio, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

AnaptysBio, Inc. has a beta of 0.286, which suggesting that the stock is 71.412% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. AnaptysBio, Inc.'s net income of $15.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.60x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -9210.61%. AnaptysBio, Inc.'s return on equity of -367.62% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

AnaptysBio, Inc. has a consensus price target of $63.91, signalling upside risk potential of 47.6%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.19 which suggests that it could grow by 158.41%. Given that Ovid Therapeutics, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.286, which suggesting that the stock is 71.412% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Ovid Therapeutics, Inc. quarterly revenues of $132K. AnaptysBio, Inc.'s net income of $15.1M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.60x versus 17.42x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -40.15%. AnaptysBio, Inc.'s return on equity of -367.62% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

AnaptysBio, Inc. has a consensus price target of $63.91, signalling upside risk potential of 47.6%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 125.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.286, which suggesting that the stock is 71.412% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. AnaptysBio, Inc.'s net income of $15.1M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.60x versus 1.44x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -876.34%. AnaptysBio, Inc.'s return on equity of -367.62% beat Verastem, Inc.'s return on equity of -1773.4%.

AnaptysBio, Inc. has a consensus price target of $63.91, signalling upside risk potential of 47.6%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 50.94%. Given that Verastem, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Verastem, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.286, which suggesting that the stock is 71.412% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. AnaptysBio, Inc.'s net income of $15.1M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.60x versus 49.53x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.